Intravenous immunoglobulin reviews

The resuspended and formulated Fraction II precipitate normally contains some aggregated IgG and trace substances that can cause hypotensive reactions in patients, such as the enzyme prekail ikrein activator (186). These features restrict this type of product to intramuscular adininistration. Further processing is required if products suitable for intravenous adininistration are required. Processes used for this purpose include treatment at pH 4 with the enzyme pepsin [9001-75-6] being added if necessary (131,184), or further purification by ion-exchange chromatography (44). These and other methods have been fiiUy reviewed (45,185,187,188). Intravenous immunoglobulin products are usually suppHed in the freeze-dried state but a product stable in the solution state is also available (189). 

Immunoglobulin preparations are concentrated protein solutions derived from the pooled plasma of adults or animals. They contain specific antibodies in proportion to the infectious and immunization experience of the population from whose plasma they are prepared (1). Large numbers of donors (at least 1000 donors per lot of final product) are used, in order to ensure inclusion of a broad spectrum of antibodies. Intravenous immunoglobulin is also derived from the pooled plasma of adults, but the alcohol-fractionation procedure is modified to a product suitable for intravenous use. The use of intravenous immunoglobulins in selected immunodeficiency and autoimmune diseases has been reviewed (2). 

The use of intravenous immunoglobulins in selected immunodeficiency and autoimmune diseases has been reviewed (2). 

In two reviews of intravenous immunoglobulin in systemic lupus erythematosus, there was worsening proteinuria and/or a rise in serum creatinine (127,128), whereas others treating similar patients did not detect deterioration (117,129). 

Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin a report of three patients and review of the literature. Br J Dermatol 2000 142(3) 551. ... 

Wiles CM, Brown P, Chapel H, Guerrini R, Hughes RA, Martin TD, McCrone P, Newsom-Davis J, Palace J, Rees JH, Rose MR, Scolding N, Webster AD. Intravenous immunoglobulin in neurological disease a specialist review. J Neurol Neurosurg Psychiatry 2002 72(4) 440-8. 

Crouch ED, Watson LE. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura—a case report and literature review. Angiology 2002 53(1) 113-17. 

Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000 75(l) 83-5. 

Itkin YM and Trujillo TC. Intravenous immunoglobulin-associated acute renal failure case series and literature review. Phama-cotherapy 2005 25 886-892... 

Hematologic A 3-year-old boy developed immune thrombocytopenic purpura 26 days after a second dose of seasonal influenza vaccine [12. He was given intravenous immunoglobulin and recovered within 2 days. A literature review showed that symptomatic thrombocytopenia occurs in a substantial number of children and adults who require hospitalization for complicated natural influenza infections. In contrast, reports of immune thrombocytopenic purpura after influenza immunization are rare and occur in adults. 

The clinical characteristics and treatment of the anticonvulsant hypersensitivity syndrome have been reviewed. Treatment with A-acetylcysteine and intravenous immunoglobulin is suggested. The rationale for this relies on the scavenging properties of N-acetylcysteine and on modulation of the over-reactive immune system by immunoglobulin [71 ]. 

Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus bl9 infection a retrospective study of 10 patients and review of the literature. Clin Infect Dis April 2013 56(7) 968-77. 

Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients a case report and discussion of the relevant literature. Ann Hematol October 2004 83(10) 661-5. [Case Reports Review]. 

Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immtmoglobulin in treatment of primary antibody deficiencies systematic review and meta analysis. J Clin Immunol December 2012 32(6) 1180-92. 

---